Park Ha Biological Technology (BYAH) Common Equity (2023 - 2026)

Park Ha Biological Technology has reported Common Equity for 4 years, with the latest figure at $5.4 million in Q2 2026.

• On a quarterly basis, Common Equity rose 26.75% year-over-year to $5.4 million in Q2 2026; TTM through Apr 2026 was $5.4 million, a 26.75% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 165.25% from the prior year.
• Common Equity was $5.4 million for Q2 2026 at Park Ha Biological Technology, up from $4.0 million in the prior quarter.
• The five-year high for Common Equity was $5.4 million in Q2 2026, with the low at $1.0 million in Q4 2023.
• Average Common Equity over 4 years is $3.2 million, with a median of $4.0 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Common Equity jumped 165.25% in 2025, then increased 26.75% in 2026.
• Over 4 years, Common Equity stood at $1.0 million in 2023, then jumped by 48.75% to $1.5 million in 2024, then surged by 165.25% to $4.0 million in 2025, then surged by 34.86% to $5.4 million in 2026.
• The last three Common Equity figures came in at $5.4 million (Q2 2026), $4.0 million (Q4 2025), and $4.3 million (Q2 2025), per Business Quant data.